Skip to main content
menu

Daniel L. Mulkerin, M.D.

Contact Information

Phone Numbers

Office: (585) 275-5823

Fax: (585) 670-0026

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

Professional Background

Dr. Mulkerin's clinical practice is focused on gastrointestinal malignancies. He is actively involved in clinical research. He is a highly respected mentor and has extensive teaching experience. Dr. Mulkerin holds an important role in enhancing and advancing the Department of Medicine's footprint in our region.

Credentials

Specialties

    Education

    1992
    MD | Thomas Jefferson University Hospital

    Post-doctoral Training & Residency

    07/01/1996 - 06/30/1999
    Fellowship in Medical Oncology at University of Wisconsin Hospital and Clinics

    06/25/1993 - 06/30/1996
    Residency in Internal Medicine at University of Wisconsin Hospital and Clinics

    06/24/1992 - 06/24/1993
    Internship in Internal Medicine at University of Wisconsin Hospital and Clinics

    VIEW ALL expand_more

    Awards

    2017 - 2018
    Award for Service/Leadership Excellence

    2016
    UW Health Patient Experience Physician Champion Award

    2015
    UW Health Physician Excellence Regional Services Award

    2014
    UW Health Patient Experience Physician Champion Award

    2013 - 2021
    Best Doctor's in America

    2006
    Top Doctors: Madison Magazine

    1992
    Hobart Armory Hare Honor Society
    Location: Jefferson Medical College


    UW Hematology/Oncology Division/Department of Medicine

    VIEW ALL expand_more

    Clinical Trials

    A Phase 1b/2 Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma

    Lead Researcher: Daniel L Mulkerin

    This trial will assess the safety and tolerability of Pepinemab in combination with Avelumab in patients with metastatic pancreatic adenocarcinoma that has progressed after first line chemotherapy. Phase 2 will assess the efficacy of this combination therapy.

    View Study Details

    A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

    Lead Researcher: Daniel L Mulkerin

    This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).

    View Study Details

    Publications

    Journal Articles

    7/2022
    Krause D, Sharrah K, Gross A, Bowers D, Mulkerin D, Brandt N, Kennedy K, Austin A, Begue A, Bell R, Raczyk C, Pickard T, Kubal T, Johnson D, Jeffries K, Dest V, Randall R, Sugalski J, Zecha G. "Measuring Advanced Practice Provider Productivity at the National Comprehensive Cancer Network's Member Institutions." Journal of the advanced practitioner in oncology.. 2022 Jul; 13(5):507-513. Epub 2022 Jul 27.

    6/2022
    Emamekhoo H, Carroll CB, Stietz C, Pier JB, Lavitschke MD, Mulkerin D, Sesto ME, Tevaarwerk AJ. "Supporting Structured Data Capture for Patients With Cancer: An Initiative of the University of Wisconsin Carbone Cancer Center Survivorship Program to Improve Capture of Malignant Diagnosis and Cancer Staging Data." JCO clinical cancer informatics.. 2022 Jun; 6:e2200020.

    9/2021
    Austin A, Jeffries K, Krause D, Sugalski J, Sharrah K, Gross A, Bowers D, Mulkerin D, Brandt N, Begue A, Bell R, Raczyk C, Pickard T, Johnson D, Dest V, Randall R, Zecha G, Kennedy K. "A Study of Advanced Practice Provider Staffing Models and Professional Development Opportunities at National Comprehensive Cancer Network Member Institutions." Journal of the advanced practitioner in oncology.. 2021 Sep; 12(7):717-724. Epub 2021 Sep 01.

    VIEW ALL PUBLICATIONS

    Reviews

    At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.